Drug Profile
FPT 155
Alternative Names: CD80-Fc; FPT-155Latest Information Update: 04 Nov 2022
Price :
$50
*
At a glance
- Originator Five Prime Therapeutics
- Class Antibodies; Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action CD28 antigen stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer; Solid tumours
Most Recent Events
- 04 Nov 2022 Discontinued - Phase-I for Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Australia, South Korea (Parenteral) (Amgen pipeline, November 2022)
- 04 Nov 2022 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in South Korea, Australia (Parenteral) (Amgen pipeline, November 2022)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Australia (Parenteral)